GLP-1 Weight Loss Therapy

Minmed Group offers medically supervised GLP-1 receptor agonist therapy as part of its Medical Weight Management programme for patients who meet clinical eligibility criteria. GLP-1 (glucagon-like peptide-1) medications mimic a natural gut hormone that regulates appetite, slows gastric emptying, and improves insulin sensitivity — making them among the most clinically proven pharmacological tools for obesity management available today.

Commonly prescribed GLP-1 agents include semaglutide (the active ingredient in Ozempic and Wegovy) and liraglutide (Saxenda). Both are administered by subcutaneous injection — semaglutide typically once weekly and liraglutide once daily — and are titrated gradually upward over several weeks to maximise tolerability and therapeutic effect.

At Minmed, the prescribing physician conducts a thorough pre-treatment assessment to confirm suitability for GLP-1 therapy: ruling out contraindications such as personal or family history of medullary thyroid carcinoma, MEN2 syndrome, pancreatitis, or severe gastrointestinal disease. Blood tests review fasting glucose, HbA1c, lipid profile, and renal and liver function to establish a baseline and identify any concurrent metabolic conditions that GLP-1…